Table 3 Histopathological findings
From: 5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity
5ARI users | Non-5ARI users | |||||||
|---|---|---|---|---|---|---|---|---|
PIRADS 1–2 or no lesions (n = 3) | PIRADS 3 (n = 23) | PIRADS 4 (n = 21) | PIRADS 5 (n = 7) | PIRADS 1–2 or no lesions (n = 27) | PIRADS 3 (n = 88) | PIRADS 4 (n = 145) | PIRADS 5 (n = 37) | |
Any prostate cancer detected | 0 | 8 (34.8%) | 12 (57.1%) | 5 (71.5%) | 10 (37.0%) | 38 (43.1%) | 118 (81.4%) | 36 (97.3%) |
Prostate cancer detected on targeted biopsies | 0 | 5 (21.7%) | 10 (47.6%) | 4 (57.1%) | 0 | 26 (29.5%) | 93 (64.1%) | 36 (97.3%) |
Prostate cancer detected on saturation biopsies | 0 | 7 (30.4%) | 10 (47.6%) | 4 (57.1%) | 10 (37.0%) | 32 (36.4%) | 112 (77.2%) | 31 (83.8%) |
Clinically significant prostate cancer detected | 0 | 2 (8.70%) | 10 (47.6%) | 5 (71.5%) | 4 (14.8%) | 18 (20.4%) | 82 (56.6%) | 31 (83.8%) |